Associate Director, Translational Medicine Lead

AstraZeneca•South San Francisco, CA
•$142,378 - $213,566

About The Position

AstraZeneca is seeking an Associate Director, Translational Medicine Lead to develop and lead hypothesis-driven biomarker strategies and translational science for B-cell malignancy programs, including B-ALL, B-CLL, and non-Hodgkin lymphoma, as well as combination therapy studies. The role translates disease biology and therapeutic mechanisms into plans for patient stratification and selection, target engagement, pharmacodynamic assessment, response depth and durability, and mechanisms of resistance. It is a 100% Translational Medicine role supporting large molecules—including T-cell-engaging bispecifics, antibody-drug conjugates, and monoclonal antibodies—as well as small molecules and cell-based therapies. The role owns translational strategy for assigned programs and clinical trials and represents Translational Medicine on cross-functional teams from preclinical development through Phase 1/2 and, where needed, Phase 3. The successful candidate brings established expertise in B-cell disease biology, experience with T-cell-engaging bispecifics and ADCs, and a track record of delivering biomarker strategies in hematology drug development. The position is based in Gaithersburg, Maryland, or South San Francisco, California; the location is flexible.

Requirements

  • PhD in a relevant biological science, such as hematology-oncology, immunology, oncology, molecular biology, or a related field; postdoctoral and/or industry experience is required.
  • Established knowledge of B-cell malignancy biology across B-ALL, B-CLL, and NHL, including disease pathogenesis, standard-of-care landscape, and therapeutic resistance mechanisms.
  • In-depth understanding of immunology and the tumor microenvironment in B-cell cancers, with the ability to apply this knowledge to translational strategy and biomarker design.
  • Demonstrated experience with T-cell-engaging bispecifics, such as CD3-targeting bispecifics or BiTEs, in an oncology or hematology development context; required.
  • Demonstrated experience with ADCs in a hematology or oncology development context; required.
  • 3–5 years of experience contributing to early-phase oncology clinical trials, including biomarker plan development, protocol input, and sample analysis.
  • Expertise in biomarker technologies relevant to hematologic cancers, such as flow cytometry, immunohistochemistry, molecular profiling, NGS, ctDNA, MRD assessment, cytokine and immune profiling, and other omics-based approaches.
  • Emerging understanding of the end-to-end clinical development process, from dose escalation through registration, and the strategic role of biomarkers at each stage.
  • Ability to work independently and deliver translational programs with regular managerial support, using sound scientific judgment and prioritization without close oversight.
  • Proven ability to work effectively and demonstrate scientific leadership in cross-functional program teams in a matrixed pharma or biotech environment.
  • Understanding of the roles of Clinical, Operations, Project Management, and HBS Clinical functions in delivering translational work.
  • Ability to present and integrate scientific data across experiments to support a cohesive program narrative and articulate implications for Go/No-Go decisions, including risks and caveats.
  • Excellent communication and presentation skills for internal stakeholders and emerging external scientific audiences; comfort representing Translational Medicine in cross-functional governance settings.
  • Emerging awareness of broader AstraZeneca functions, including Regulatory, Medical, and Commercial, and how Translational Medicine outputs inform those stakeholders.

Nice To Haves

  • Experience with small-molecule hematology therapeutics in B-cell malignancies, such as BTK inhibitors or BCL-2 inhibitors, and familiarity with combination treatment strategies.
  • Exposure to cell therapy programs, such as CAR-T or other engineered cell therapies, in B-cell leukemia or lymphoma.
  • Familiarity with MRD methodologies, including flow cytometry and/or NGS-based methods, in leukemia or lymphoma clinical development.
  • Experience integrating multi-omic biomarker data, such as flow cytometry, ctDNA, cytokine panels, and transcriptomics, to support clinical decisions across combination regimens.
  • Familiarity with regulatory expectations for biomarker analytical validation and companion diagnostic development.
  • Early experience mentoring junior scientists and interest in contributing to team capability development.
  • Exposure to Phase 3 trial biomarker strategies.

Responsibilities

  • Develop and own translational science strategies for assigned B-cell malignancy programs, from preclinical stages through Phase 1/2 and Phase 3 clinical studies.
  • Generate and integrate disease-linkage data to support indication selection, patient stratification, and targeted-population definition for monotherapy and combination studies.
  • Measure and interpret target engagement, pharmacodynamic biomarkers, and mechanism-of-action data to inform dose selection and clinical decisions across concurrent programs or trials.
  • Define and investigate resistance mechanisms to B-cell-targeted therapies across modalities using longitudinal and relapse clinical samples.
  • Analyze B-cell tumor biology, cancer pathway interactions, and tumor microenvironment features in patient samples to guide drug-combination strategies and trial design.
  • Lead development and deployment of fit-for-purpose translational assays, including flow cytometry, IHC/IF, molecular assays, and MRD-adjacent panels, internally and through external CRO and laboratory partners.
  • Collaborate with Precision Diagnostics on sample collection, traceability, and documentation, and support companion diagnostic pathway discussions when warranted.
  • Contribute translational and biomarker content to regulatory interactions and filings, including health authority briefing materials where appropriate.
  • Represent Translational Medicine on program-level cross-functional teams and partner with Clinical Development, Oncology Research, Clinical Operations, Product Development, and other functions to align translational work with asset strategy, disease biology, and clinical milestones.
  • Embed biomarker strategies and translational endpoints in clinical protocols, sample collection manuals, statistical analysis plans, and data delivery plans for Phase 1 through Phase 3 hematology studies.
  • Contribute to broader B-cell hematology portfolio strategy by connecting program insights to indication expansion and combination hypotheses.
  • Partner with preclinical discovery teams so translational insights inform early compound selection and target validation.
  • Contribute to and ensure the quality of clinical study reports, data reviews, scientific presentations, and recommendations for program governance and Go/No-Go decisions.
  • Integrate translational findings into coherent scientific narratives for program and portfolio decision-making.
  • Communicate biomarker data to stakeholders, including governance forums and leadership teams, with attention to strategic implications, risks, and data caveats.
  • Contribute to publications and conference presentations and represent AstraZeneca in external scientific forums in B-cell malignancy translational research.

Benefits

  • Eligibility for short-term incentive bonuses.
  • Equity-based awards for salaried roles.
  • Qualified retirement programs.
  • Paid time off, including vacation, holidays, and leaves.
  • Health coverage.
  • Dental coverage.
  • Vision coverage.
© 2026 Teal Labs, Inc
Privacy PolicyTerms of Service